AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 291 min read$ACOG

Opaleye Management Inc. purchased $435K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 73,738 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $5.90 ($5.73–$5.90, $0.43M total) across 3 trades over 2026-05-27 to 2026-05-29.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published May 29, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The filing provides fresh, primary‑source data on insider buying, which can be a short‑term catalyst for the stock.

02

Market read

New insider purchase of ~0.4 M USD in Alpha Cognition, modest but notable due to 10% stake, may slightly lift the stock.

03

What to watch

Potential upcoming product announcements or regulatory news for Alpha Cognition could amplify the impact of this insider stake.

Relevance 5/10Novelty 4/10Timing: after‑hours filing on 2026‑05‑29

Background

Form 4 filings disclose insider transactions; a 10% ownership stake signals a material interest in the company.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. purchased 73,738 shares of Alpha Cognition Inc. for $434,713.77, increasing its stake to 2,604,107 shares.

Expected impact

likely slight upward pressure as the market prices in insider confidence

Evidence & confidence

The purchase is a small‑scale Form 4 filing ($0.4 M) but represents a 10% ownership stake, which can be viewed positively by investors.

Market effects

Sector

Minimal; reflects insider confidence in a niche AI‑cognition firm but does not affect the broader sector.

Regional

None; the filing is U.S.‑focused and does not influence regional markets.

Global

Low; limited to Alpha Cognition shareholders and potential short‑term traders.

Counterpoint

What could challenge this read

The purchase size is modest; the market may have already priced in insider activity, limiting any price move.

Key entities

  • Company
    Alpha Cognition Inc.

    Issuer of the securities purchased.

  • Insider/Investor
    Opaleye Management Inc.

    Entity reporting the purchase under a 10b5‑1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min